Solian is indicated as a treatment for acute and chronic schizophrenia characterized by both negative and positive symptoms, while Stilnox is used for the treatment of insomnia and sleep disorders.
Under the contract, the products will be marketed by Multicare’s CNS Business Unit.
Multicare president Romey Sy said Multicare has four key strategic business units focused on Women’s Health, Pediatrics, Respiratory, GI, Diabetes Care & CNS.